Journal of the Korean Academy of Child and Adolescent Psychiatry

대한소아청소년정신의학회 (Korean Academy of Child and Adolescent Psychiatry)
권호 표지
DOI QR코드

DOI QR Code

Long-Term Tolerability of Escitalopram in Korean Adolescents

  • Goo, Ae-Jin (Department of Mental Health, Seoul National Hospital) ;
  • Won, Eun-Kyung (Department of Child Psychiatry, Seoul National Hospital) ;
  • Lee, Cheolsoon (Department of Psychiatry, Gyeongsang University College of Medicine) ;
  • Lee, Jong-Il (Department of Mental Health, Seoul National Hospital) ;
  • Jung, Hee-Yeon (Department of Neuropsychiatry, SMG-SNU Boramae Medical Center, College of Medicine, Seoul National University) ;
  • Kim, Yeni (Department of Child Psychiatry, Seoul National Hospital)
  • 투고 : 2013.07.10
  • 심사 : 2013.10.21
  • 발행 : 2013.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : We investigated the long-term tolerability of escitalopram in Korean adolescents. Methods : The subjects were 37 adolescents, who had been diagnosed with depressive disorder in accordance to DSM-IV. Clinical effectiveness was assessed by Clinical Global Impression-Improvement (CGI-I) scale at the final follow-up visit. Tolerability was assessed through a medical record of the reason for discontinuation of escitalopram and documented adverse events. Results : The mean duration of treatment was $78.1{\pm}89.5$ days, and the mean dosage was $10.0{\pm}4.4$mg/day. Out of the total 37 patients, two (5%) patients sustained use of escitalopram. Twelve patients (32.4%) discontinued use of escitalopram due to target symptom remission, and 23 patients (61.9%) due to insufficient efficacy. Six patients (16.2%) had at least one documented adverse event. However, no suicidal ideation or self-injurious behavior was reported. Significant differences in clinical symptom improvement efficacy were seen between the patients who were receiving escitalopram for less than 8 weeks (4.3%, 1/13) and those for more than 8 weeks (92.9%, 13/14). There was no significant difference between the tolerability of monotherapy compared to the concomitant use group. Conclusion : The results of this study suggest that long-term use of escitalopram may result in superior efficacy than shortterm use, and is tolerable in Korean adolescents with depression.

키워드

참고문헌

  1. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1998;37:1234-1238. https://doi.org/10.1097/00004583-199811000-00029
  2. Dopheide JA. Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 2006;63:233-243. https://doi.org/10.2146/ajhp050264
  3. Fergusson DM, Horwood LJ, Ridder EM, Beautrais AL. Subthreshold depression in adolescence and mental health outcomes in adulthood. Arch Gen Psychiatry 2005;62:66-72. https://doi.org/10.1001/archpsyc.62.1.66
  4. Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder? Biol Psychiatry 2001;49:980-1001. https://doi.org/10.1016/S0006-3223(01)01127-1
  5. Lewinsohn PM, Pettit JW, Joiner TE Jr, Seeley JR. The symptomatic expression of major depressive disorder in adolescents and young adults. J Abnorm Psychol 2003;112:244-252. https://doi.org/10.1037/0021-843X.112.2.244
  6. Luby JL, Mrakotsky C, Heffelfinger A, Brown K, Spitznagel E. Characteristics of depressed preschoolers with and without anhedonia: evidence for a melancholic depressive subtype in young children. Am J Psychiatry 2004;161:1998-2004. https://doi.org/10.1176/appi.ajp.161.11.1998
  7. Kovacs M, Obrosky DS, Gatsonis C, Richards C. First-episode major depressive and dysthymic disorder in childhood: clinical and sociodemographic factors in recovery. J Am Acad Child Adolesc Psychiatry 1997;36:777-784. https://doi.org/10.1097/00004583-199706000-00014
  8. McCauley E, Myers K, Mitchell J, Calderon R, Schloredt K, Treder R. Depression in young people: initial presentation and clinical course. J Am Acad Child Adolesc Psychiatry 1993;32:714-722. https://doi.org/10.1097/00004583-199307000-00003
  9. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, et al. Depressed adolescents grown up. JAMA 1999;281:1707-1713. https://doi.org/10.1001/jama.281.18.1707
  10. Garnock-Jones KP, McCormack PL. Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs 2010;24:769-796. https://doi.org/10.2165/11204760-000000000-00000
  11. US FDA. Forest Pharmaceuticals I. [Cited 2013 Feb 8] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021323s2 8s29,021365s18s19lbl.pdf?utm_campaign=Google2& utm_source=fdaSearch&utm_medium=website&utm_term=lexapro&utm_content=7.
  12. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-290. https://doi.org/10.2165/00003088-200746040-00002
  13. US FDA. Forest Pharmaceuticals I. [Cited 2013 Feb 8] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018936s075s077lbl.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_ medium=website&utm_term=prozac, pediatric&utm_content=9.
  14. US FDA. Forest Pharmaceuticals I. [Cited 2013 Feb 8] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2009/021323s030s031,021365s021s022lbl.pdf.
  15. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebocontrolled multisite trial. J Am Acad Child Adolesc Psychiatry 2009;48:721-729. https://doi.org/10.1097/CHI.0b013e3181a2b304
  16. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A doubleblind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006;45:280-288. https://doi.org/10.1097/01.chi.0000192250.38400.9e
  17. Findling R, Bose A, Aquino D, Korotzer A, Tourkodimitris S. Sixmonth double-blind escitalopram treatment of depressed adolescents. Poster Presentation at American Academy of Child & Adolescent Psychiatry Annual Meeting; 2008 Oct 28. Chicago, USA:Elsevier;2008.
  18. Carandang C, Jabbal R, Macbride A, Elbe D. A review of escitalopram and citalopram in child and adolescent depression. J Can Acad Child Adolesc Psychiatry 2011;20:315-324.
  19. Stamouli SS, Yfantis A, Lamboussis E, Liakouras A, Lagari V, Tzanakaki M, et al. Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opin Pharmacother 2009;10:937-945. https://doi.org/10.1517/14656560902810375
  20. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-339. https://doi.org/10.1001/archpsyc.63.3.332
  21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington DC: American Psychiatric Press;2000.
  22. Tao R, Emslie GJ, Mayes TL, Nakonezny PA, Kennard BD. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder. J Child Adolesc Psychopharmacol 2010;20:423-430. https://doi.org/10.1089/cap.2009.0116
  23. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005;46:735-754. https://doi.org/10.1111/j.1469-7610.2005.01467.x
  24. Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 2007;17:751-760. https://doi.org/10.1089/cap.2007.0007
  25. Schirman S, Kronenberg S, Apter A, Brent D, Melhem N, Pick N, et al. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm 2010;117:139-145. https://doi.org/10.1007/s00702-009-0330-x

피인용 문헌

  1. Psychometric Properties and Factor Structures of the Korean Version of Children's Depression Rating Scale-Revised 2017, https://doi.org/10.1089/cap.2016.0183